COrticosteroid in Congenital Adrenal Hyperplasia

NCT02552251 | Unknown Phase 2

• 1 other identifier: 11-059
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Congenital adrenal hyperplasia (CAH) results from a deficiency of a key enzyme in the biosynthesis of cortisol, mainly 21-hydroxylase, resulting in its classic form a neonatal salt loss syndrome and / or a virilization syndrome in girls. The treatment of the disorder in adulthood involves administering steroidal compounds with the aim to substitute the gluco- and mineralocorticoid deficit on the one hand, and effectively curb the adrenal hyperplasia and adrenal androgen pathway in girls . The terms of glucocorticoid treatment are not clearly codified and are based on several steroidal compounds and various protocols. The advantages in terms of adrenal suppression and disadvantages - including bone and metabolic - different treatments have not been clearly established in the literature. The main objective of this study is to compare among adults with HCS in its classical form the impact on hormonal parameters adrenal suppression glucocorticoid of 3 types of treatment administered to equivalent dose and according to the usual procedures. The secondary objective is to compare in the same patients the impact of different drugs and treatments on several metabolic bone parameters. The study will include 40 adult patients bearing a HCS in its classical form and will include 3 treatment sequences of eight weeks each, during which they will be administered sequentially in random order at random and according to the known equivalences hydrocortisone, prednisone (CORTANCYL) and dexamethasone (DECTANCYL). Randomization will be stratified based on previous DMARDs in the investigation that may be different for different patients, knowing that France hydrocortisone and dexamethasone are used mainly for the treatment of congenital adrenal hyperplasia. The judging criteria will be: i) the criteria of adrenal hormone suppression: plasma levels of testosterone, androstenedione, 17 OHP, ACTH and diurnal variations of the 17 OH progesterone salivary ii) the criteria of the metabolic impact of glucocorticoids: plasma glucose levels , blood lipids, and insulin sensitivity index HOMA-R calculated from glucose and insulin, iii) the criteria of bone impact of glucocorticoids: plasma for CTX bone resorption and bone alkaline phosphatase P1NP for bone formation iv) the living quality criteria evaluated by the PGWB Questionnaire (Psychological General Well-Being). The duration of the study period will be 24 months.

Conditions

Congenital Adrenal Hyperplasia

Outcome Measures

Primary Outcomes (1)

• hormonal parameters

  6 points salivary 17 OHP cycle, and 8 am plasma ACTH,testosterone and androstenedione

  change over baseline, week 8, week 16, week 24

Secondary Outcomes (3)

• parameters of bone turnover:

  change over baseline, week 8, week 16, week 24

• metabolic parameters:

  change over baseline, week 8, week 16, week 24

• Quality of Life

  change over baseline, week 8, week 16, week 24

Study Arms (3)

A: hydrocortisone

EXPERIMENTAL

hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks

Biological: Hormonal balance measurements; Biological: metabolic balance measurements; Biological: bone balance measurements; Behavioral: quality of life assessment

B :dexamethasone (DECTANCYL)

EXPERIMENTAL

dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks

Biological: Hormonal balance measurements; Biological: metabolic balance measurements; Biological: bone balance measurements; Behavioral: quality of life assessment

C : prednisone (CORTANCYL)

EXPERIMENTAL

prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks

Biological: Hormonal balance measurements; Biological: metabolic balance measurements; Biological: bone balance measurements; Behavioral: quality of life assessment

Interventions

Hormonal balance measurements BIOLOGICAL

A: hydrocortisone; B :dexamethasone (DECTANCYL); C : prednisone (CORTANCYL)

metabolic balance measurements BIOLOGICAL

A: hydrocortisone; B :dexamethasone (DECTANCYL); C : prednisone (CORTANCYL)

bone balance measurements BIOLOGICAL

A: hydrocortisone; B :dexamethasone (DECTANCYL); C : prednisone (CORTANCYL)

quality of life assessment BEHAVIORAL

A: hydrocortisone; B :dexamethasone (DECTANCYL); C : prednisone (CORTANCYL)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Pubescent women over 18 in genital activity (premenopausal)
• Suffering from congenital adrenal hyperplasia in its classical form with salt loss or pure virilizing
• Patients who have presented signs of congenital adrenal hyperplasia in its classical form (salt wasting syndrome and / or neonatal masculinization) with elevation of 17 OH progesterone with diagnosis of enzyme block 21 hydroxylase.
• Patients currently treated by: 1 or 2 Oral compound glucocorticoid as replacement and suppressive therapy + 1 mineralocorticoid if necessary with effective control of substitution + possibly by estrogen-progestin pill.

You may not qualify if:

• Liver disease, kidney, bone, diabetes, severe dyslipidemia, pregnancy
• Postmenopausal women, age over 55 years
• Concomitant therapy: glucocorticoids supra-physiological doses for other indications, bisphosphonates, vitamin D, oral antidiabetic agents or insulin, lipid lowering agents (eg inflammatory disease, asthma, systemic disease ... ..).
• participation of the subject to another biomedical research protocol for this study
• Inability to submit to medical monitoring study for geographical, social or psychological.
• Severe calorie diet planned or carried out during the study.

Sponsors & Collaborators

• University Hospital, Caen: lead

Study Sites (1)

Service Endocrinologie et Maladies Métaboliques

Caen, 14000, France

RECRUITING

MeSH Terms

Conditions

Adrenal Hyperplasia, Congenital

Condition Hierarchy (Ancestors)

Adrenogenital Syndrome; Disorders of Sex Development; Urogenital Abnormalities; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Steroid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases; Nutritional and Metabolic Diseases; Adrenal Gland Diseases; Endocrine System Diseases; Gonadal Disorders

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2015
• First Posted: September 17, 2015
• Study Start: August 1, 2012
• Primary Completion: December 1, 2015
• Last Updated: September 17, 2015

Record last verified: 2015-09

Locations

FR (1)